Doximity, Inc. (DOCS)
NYSE: DOCS · Real-Time Price · USD
50.97
-0.10 (-0.20%)
At close: Nov 26, 2025, 4:00 PM EST
50.32
-0.65 (-1.28%)
After-hours: Nov 26, 2025, 7:00 PM EST
Doximity Revenue
Doximity had revenue of $168.53M in the quarter ending September 30, 2025, with 23.16% growth. This brings the company's revenue in the last twelve months to $621.33M, up 20.21% year-over-year. In the fiscal year ending March 31, 2025, Doximity had annual revenue of $570.40M with 19.98% growth.
Revenue (ttm)
$621.33M
Revenue Growth
+20.21%
P/S Ratio
15.41
Revenue / Employee
$748,589
Employees
830
Market Cap
9.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 570.40M | 94.98M | 19.98% |
| Mar 31, 2024 | 475.42M | 56.37M | 13.45% |
| Mar 31, 2023 | 419.05M | 75.50M | 21.98% |
| Mar 31, 2022 | 343.55M | 136.65M | 66.05% |
| Mar 31, 2021 | 206.90M | 90.51M | 77.76% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
DOCS News
- 19 days ago - Doximity, Inc. (DOCS) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Doximity Announces Fiscal 2026 Second Quarter Financial Results - Business Wire
- 4 weeks ago - Halper Sadeh LLC Encourages Doximity Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 5 weeks ago - Doximity to Release Fiscal 2026 Second Quarter Results on November 6, 2025 - Business Wire
- 2 months ago - Doximity, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation - Business Wire
- 3 months ago - Doximity Analysts Increase Their Forecasts After Strong Q1 Earnings - Benzinga
- 3 months ago - Doximity, Inc. (DOCS) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Doximity (DOCS) Q1 Revenue Rises 15% - The Motley Fool